# Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer

> **NCT00402883** · PHASE2 · TERMINATED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 5 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Pemetrexed
- **PROCEDURE:** Radiotherapy
- **OTHER:** Folic Acid
- **OTHER:** vitamin B12
- **DRUG:** carboplatin

## Key facts

- **NCT ID:** NCT00402883
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Terminated due to bevacizumab and chemoradiotherapy toxicity
- **Last updated:** 2021-11-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00402883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00402883, "Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00402883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*